- Original research
- Open Access
Synthesis and preclinical evaluation of novel 99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer
EJNMMI Research volume 13, Article number: 2 (2023)
Radioguided surgery (RGS) has recently emerged as a valuable new tool in the management of recurrent prostate cancer (PCa). After preoperative injection of a 99mTc-labeled prostate-specific membrane antigen (PSMA) inhibitor, radioguided intraoperative identification and resection of lesions is facilitated by means of suitable γ-probes. First clinical experiences show the feasibility of RGS and suggest superiority over conventional lymph node dissection in recurrent PCa. However, commonly used [99mTc]Tc-PSMA-I&S exhibits slow whole-body clearance, thus hampering optimal tumor-to-background ratios (TBR) during surgery. We therefore aimed to develop novel 99mTc-labeled, PSMA-targeted radioligands with optimized pharmacokinetic profile to increase TBR at the time of surgery.
Three 99mTc-labeled N4-PSMA ligands were preclinically evaluated and compared to [99mTc]Tc-PSMA-I&S. PSMA affinity (IC50) and internalization were determined on LNCaP cells. Lipophilicity was assessed by means of the distribution coefficient logD7.4 and an ultrafiltration method was used to determine binding to human plasma proteins. Biodistribution studies and static µSPECT/CT-imaging were performed at 6 h p.i. on LNCaP tumor-bearing CB17-SCID mice.
The novel N4-PSMA tracers were readily labeled with [99mTc]TcO4− with RCP > 95%. Comparable and high PSMA affinity was observed for all [99mTc]Tc-N4-PSMA-ligands. The ligands showed variable binding to human plasma and medium to low lipophilicity (logD7.4 − 2.6 to − 3.4), both consistently decreased compared to [99mTc]Tc-PSMA-I&S. Biodistribution studies revealed comparable tumor uptake among all [99mTc]Tc-N4-PSMA-ligands and [99mTc]Tc-PSMA-I&S, while clearance from most organs was superior for the novel tracers. Accordingly, increased TBR were achieved. [99mTc]Tc-N4-PSMA-12 showed higher TBR than [99mTc]Tc-PSMA-I&S for blood and all evaluated tissue. In addition, a procedure suitable for routine clinical production of [99mTc]Tc-N4-PSMA-12 was established. Labeling with 553 ± 187 MBq was achieved with RCP of 98.5 ± 0.6% (n = 10).
High tumor accumulation and favorable clearance from blood and non-target tissue make [99mTc]Tc-N4-PSMA-12 an attractive tracer for RGS, possibly superior to currently established [99mTc]Tc-PSMA-I&S. Its GMP-production according to a method presented here and first clinical investigations with this novel radioligand is highly recommended.
Throughout the last decade, radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have become an integral part in clinical management of prostate cancer (PCa) [1, 2]. Almost in parallel with the clinical success of diagnostic tracers such as [68Ga]Ga-PSMA-11  and [18F]DCFPyL  for positron emission tomography (PET) or [99mTc]Tc-MIP-1404  for single-photon emission computed tomography (SPECT) imaging, several therapeutic compounds entered the stage, among them 177Lu-labeled PSMA-I&T and PSMA-617 [6, 7]. In addition, several distinct therapeutic approaches have found their way into preclinical and clinical research, among them long-acting albumin-binding PSMA-ligands [8, 9], targeted alpha therapy  or so-called tandem therapy combining [225Ac]Ac- and [177Lu]Lu-PSMA-617 . The recent approval of [177Lu]Lu-PSMA-617 (Pluvicto™, Novartis) for RLT of metastatic castration-resistant PCa (mCRPC) represents a milestone for nuclear medicine, broadens the armamentarium of oncologists, and might pave the way for further approved targeted therapeutic radiopharmaceuticals.
Radioguided surgery (RGS) is another therapeutic intervention successfully harnessing the potential of radioactive PSMA-targeted probes . Patients with early biochemical recurrence after radical prostatectomy that show only regional pelvic lymph node metastases (LNM) in PSMA-PET imaging can benefit from radioguided salvage lymph node dissection (sLND) to delay disease progression and future systemic treatment . In contrast to conventional sLND, a γ-emitting PSMA-targeted radioligand is intravenously injected up to 24 h prior to surgery. With the help of a γ-probe, localization and resection of metastatic lymph nodes are facilitated during surgery, which is especially useful in the case of small or atypically localized lesions. Furthermore, resected tissue can be identified instantly by ex vivo γ-probe measurements to confirm the successful removal of tumor-infested tissue. After initial proof-of-concept with [111In]In-PSMA-I&T , PSMA-RGS has been carried out with [99mTc]Tc-PSMA-I&S , owing to its similar performance in vivo and more favorable radiation properties, the more common allowance to work with 99mTc-tracers in surgery rooms, lower costs and higher availability of [99mTc]TcO4− compared to [111In]InCl3. A recent study with 121 patients by Horn et al. described the successful removal of preoperatively identified lesions in 99% of patients and a complete biochemical response in 66% of patients , which confirms results reported earlier by Maurer et al. for a smaller group of patients . In the latter study, even additional lesions not previously detected on PSMA-PET could be removed, which highlights the potential of RGS for sLND . However, prospective clinical trials such as the TRACE study (NCT03857113) are required to accurately assess the long-term outcome and added benefit of RGS for PCa patients.
Whether conventional or radioguided, the main limitation of sLND procedures is constituted in the incomplete resection of metastatic lesions. Even though state-of-the-art PSMA radio-guidance using [99mTc]Tc-PSMA-I&S showed superior short-term efficacy in terms of biochemical response in a prospective study by Knipper et al. , the still insufficient sensitivity with regard to micro-metastatic lesions seems to be a major reason for recurrent disease [13, 18]. Technological developments like robot-assisted laparoscopic surgery implying drop-in or click-on γ-probes  and more differentiated criteria for patient selection  can certainly move the application forward. However, on a radiopharmaceutical level we identified a pending need of improvement, namely a radiotracer providing higher contrast and lower background signal than currently applied [99mTc]Tc-PSMA-I&S. Its comparably slow whole-body clearance and partial hepatobiliary excretion is caused by high plasma protein binding (PPB) of 94% and reduced hydrophilicity compared to DOTA-based PSMA-radiochelated tracers . As a result, unspecific background signal hampers both contrast in early SPECT-imaging and accurate detection during surgery [21, 22]. Thus, often [99mTc]Tc-PSMA-I&S is not used to reliably identify LNMs in situ during surgery, but rather to confirm PSMA-positivity of resected tissue ex vivo. However, technically a more accurate lesion detection even in the surgical field should be feasible if TBR are sufficiently high, and thus, even smaller lesions might become detectable with an appropriately performing radiotracer. In spite of the known limitations of [99mTc]Tc-PSMA-I&S, to our knowledge, no dedicated optimization of a 99mTc-labeled PSMA-ligand intended for RGS application has been performed so far.
To address this medical need, we developed a novel series of 99mTc-labeled PSMA-targeted radioligands for RGS aiming for an improved pharmacokinetic behavior. The optimized ligand structure was conceptually designed and comprises a common PSMA-inhibitor motif derived from highly potent radiohybrid PSMA diagnostics  and therapeutics , a tetraamine (N4) chelator for reliable complexation of technetium-99m, and a variable amino acid for the modulation of pharmacokinetic properties of the peptide (Fig. 1). Such rational and iterative modifications constitute the core of radiopharmaceutical structure development and a multitude of studies have brought forth interesting PSMA radioligands for manifold applications using that approach [25,26,27]. As we aimed for differential (and primarily reduced) lipophilicity and plasma protein binding of the novel ligands, d-glutamate (d-Glu; negatively charged), d-phenylalanine (d-Phe; aromatic, uncharged), and 4-amino-d-phenylalanine (d-(4-NH2)Phe; aromatic, positively charged) were used as variable amino acids to introduce different charges and optional aromatic moieties.
In this study, we report the comparative preclinical evaluation of three 99mTc-labeled N4-PSMA ligands in vitro and in vivo. All experiments were performed in comparison with [99mTc]Tc-PSMA-I&S, the current clinical standard for PSMA-targeted RGS. In preparation of first clinical studies, we furthermore established a labeling procedure of the most promising derivative at patient scale that should be suited for routine clinical radioligand production.
Materials and methods
Further general information and a detailed description of ligand synthesis are provided in Additional file 1.
99mTc-Labeling of N4-PSMA ligands was carried out by addition of 1 nmol peptide precursor (0.5 mM in DMSO) to a mixture of 0.05 M Na2HPO4 (12.5 µL, in Tracepur®-water, pH 9.25) and 0.1 M disodium citrate sesquihydrate (1.5 µL, in Tracepur®-water) in saline. After addition of a freshly prepared solution of SnCl2 (2.5 µL, 1 mg/mL in ethanol), [99mTc]TcO4− (40 MBq/nmol) in saline was added and the labeling solution (final volume 250 µL) was heated to 95 °C for 15 min. Subsequently, 10 µL of 1 M sodium ascorbate (in PBS) was added and quality control was performed using radio-TLC and radio-RP-HPLC (UV-detection at 220 nm). A slightly modified protocol for radiolabeling at patient scale and labeling of PSMA-I&S are described in Additional file 1.
Lipophilicity and binding to human plasma
The lipophilicity of 99mTc-labeled PSMA ligands, expressed as distribution coefficient (logD7.4), was determined using the shake-flask method. A solution of approximately 1 MBq of radioligand in 1 mL of a 1:1 mixture of PBS (pH = 7.4) and n-octanol (n = 8) was vortexed vigorously for 3 min. After centrifugation at 9000 rpm for 5 min aliquots of both phases (200 µL n-octanol, 50 µL PBS) were collected and the activity was quantified in a γ-counter. logD7.4 values were calculated as decadic logarithm of the activity concentration ratio between the n-octanol phase and the aqueous phase. Data are given as mean ± standard deviation (SD).
Binding to human plasma was determined by incubation of radioligands in human plasma (2 nM concentration, 37 °C for 30 min) and subsequent ultrafiltration (250 µL aliquots, 3200 rpm, 40 min) in Centrifree® ultrafiltration devices (Merck Millipore, Cork, Ireland). The fraction bound to human plasma proteins was calculated as the ratio of unfiltered activity and the total activity in the ultrafiltration device. Measurements were performed in three independent experiments, each with two replicates (n = 6, data are given as mean ± SD). All values were corrected for non-specific binding (control experiments in PBS).
Determinations of affinities (IC50) and internalization studies
Competitive binding studies were carried out in analogy to a previously reported procedure . As a modification the non-radiolabeled standard competitor (((S)-1-carboxy-5-(4-(iodo)benzamido)pentyl)carbamoyl)-l-glutamic acid (IBA-KuE) was applied in increasing concentrations (10–5–10–11 M/well, n = 3 each) whereas the novel PSMA-binding compounds of interest were applied as 99mTc-labeled radioligands (0.2 nM/well). In this inversed experimental approach, higher values correspond to higher affinities and are referred to as inverse IC50. Poly-L-lysine coated 24-well plates were used (n = 3). Data are given as mean ± SD. To determine the cellular uptake of the 99mTc-labeled PSMA ligands into LNCaP cells by means of PSMA-mediated internalization at 1 h, a previously reported protocol was applied with assay concentrations of 1.0 nM and 0.2 nM for 99mTc-labeled PSMA ligands and the reference compound [125I]IBA-KuE, respectively . Data are corrected for non-specific binding and normalized to the specific internalization of the reference. Results are given as mean ± SD.
In vivo experiments
All animal experiments were conducted in accordance with general animal welfare regulations in Germany (German animal protection act, in the edition of the announcement, dated May 18th, 2006, as amended by Article 280 of June 19th 2020, approval no. ROB-55.2-1-2532.Vet_02-18-109 by the General Administration of Upper Bavaria) and the institutional guidelines for the care and use of animals. Male CB17-SCID mice were purchased from Charles River (Sulzfeld, Germany) and arrived at the in-house animal facility to acclimate at least 1 week before the start of the experiment. Tumor xenografts were established by subcutaneous inoculation of LNCaP cells (approx. 2 × 107 cells in 200 µL of a 1:1 mixture of Cultrex BME (R&D Systems, Minneapolis, United States) and DMEM/Ham’s F-12) onto the right shoulder of 6–8 weeks old male CB17-SCID mice. The animals were used for experiments when tumors had grown to a size of 5–10 mm in diameter. Criteria for the exclusion of animals from the experiment were weight loss higher than 20%, tumor size above 1.5 cm3, ulceration of the tumor, respiratory distress or change of behavior. These criteria did not apply to any mouse. Neither randomisation nor blinding was applied in the allocation of the experiments. Quarterly health monitoring was performed according to the FELASA recommendations.
The 99mTc-labeled radioligands (2.7 ± 0.7 MBq, 82 ± 20 pmol) were injected into a lateral tail vein of LNCaP-tumor bearing mice (n = 4–5) under isoflurane anesthesia. Animals were sacrificed at 6 h post injection (p.i.) by carbon dioxide inhalation and blood withdrawal via cardiac puncture. Blood and tissues of interest were collected, weighed and the activity measured in a γ-counter. Radioligand uptake is given in percent of the injected dose per gram of tissue (% ID/g) and results are presented as mean ± SD. Further details on the analysis of biodistribution data are provided in Additional file 1: Fig. S1.
Static imaging of sacrificed animals was performed on a VECTor4 small-animal SPECT/PET/CT/OI scanner from MILabs (Utrecht, Netherlands) directly after blood collection with an acquisition time of 45 min using an HE-GP-RM collimator and a step-wise multiplanar bed movement via MILabs acquisition software (v11.00 and v12.26). Imaging data were reconstructed using MILabs-Reconstruction software (v12.00) and image analysis was performed with PMOD4.0 (PMOD technologies LLC, Zurich, Switzerland). Animals were subjected to biodistribution studies after imaging.
Acquired data were statistically analyzed performing a one-way analysis of variances (ANOVA) followed by a Tukey’s multiple comparison post-test using OriginPro software (version 9.7) from OriginLab Corporation (Northampton, United States). Pairwise statistical comparisons were performed applying the two-sample student’s t-test in Microsoft Excel (Redmond, United States). Acquired P values of < 0.05 were considered statistically significant.
Synthesis and radiolabeling
The novel PSMA ligands were synthesized using a mixed solution/solid phase synthetic approach and obtained with chemical purity of > 98% in yields of 29%, 25% and 21%, respectively. Compound identity was confirmed by mass spectrometry. Radiolabeling with [99mTc]TcO4− resulted in radiochemical purities (RCP) of > 95% as determined by radio-TLC and radio-RP-HPLC. Up-scaling of the reported labeling protocol for patient-scale production of [99mTc]Tc-N4-PSMA-12 was found to be feasible, however proportionally reduced amounts of stannous chloride were applied to prevent the formation of colloidal technetium-species. Under consideration of requirements of a clinical workflow for routine radiosynthesis, labeling of N4-PSMA-12 (20 µg, 15 nmol) with activities of 194–810 MBq (553 ± 187 MBq, mean ± SD, n = 10) reproducibly yielded the desired radioligand with a RCP of 98.5 ± 0.6% (range, 97.6–99.2%, n = 10). Detailed information on single radiolabelings is provided in Additional file 1: Table S1.
In Vitro Characterization
Results of the in vitro characterization of [99mTc]Tc-labeled N4-PSMA ligands and the reference [99mTc]Tc-PSMA-I&S are summarized in Fig. 2 and Additional file 1: Table S2. PSMA affinity was assessed via determination of the inverse IC50 (IC50,inv). Irrespective of the variable amino acid, all radioligands showed high PSMA affinity displayed by low nanomolar IC50,inv. values (range, 10.0–11.8 nM) with no statistically significant difference (P > 0.66). In contrast, PSMA mediated internalization, expressed as percentage of the reference compound [125I]IBA-KuE, was significantly influenced by the variable amino acid. [99mTc]Tc-N4-PSMA-12 (311 ± 16%) exhibited 1.3-fold higher internalization than [99mTc]Tc-PSMA-I&S (240 ± 13%), and an even 1.9- and 1.7-fold higher value than [99mTc]Tc-N4-PSMA-13 (164 ± 15%) and [99mTc]Tc-N4-PSMA-21 (180 ± 4%), respectively. In comparison with [99mTc]Tc-PSMA-I&S, all novel [99mTc]Tc-N4-PSMA compounds showed increased hydrophilicity, expressed by the distribution coefficient (logD7.4). Within the group of N4-bearing radioligands, highest lipophilicity was observed for [99mTc]Tc-N4-PSMA-13 (logD7.4 = − 2.78 ± 0.05), comprising an aromatic d-Phe residue, followed by [99mTc]Tc-N4-PSMA-21 (logD7.4 = − 3.13 ± 0.05, d-(4-NH2)-Phe) and [99mTc]Tc-N4-PSMA-12 (logD7.4 = − 3.35 ± 0.05, d-Glu). Compared to [99mTc]Tc-PSMA-I&S, binding to human plasma was significantly reduced for all [99mTc]Tc-N4-PSMA tracers (94.4% vs 55.1–88.5%), and followed the same trend as described for lipophilicity. Thus, the highest hydrophilicity (logD7.4 = − 3.35 ± 0.05) and lowest binding to human plasma proteins (55.1 ± 2.5%) was both found for [99mTc]Tc-N4-PSMA-12 (P < 0.001 for both parameters).
In vivo characterization
Comparative biodistribution studies in LNCaP tumor-bearing mice at 6 h p.i. were performed for all four radiotracers (Fig. 3, Additional file 1: Table S3).
Among the three N4-bearing radioligands, a similar distribution profile with high uptake in the tumor (11.0–13.0% ID/g), varying but moderate activity levels in the kidneys and efficient clearance from blood and background tissue was observed (see also µSPECT/CT-scans in Fig. 4). [99mTc]Tc-N4-PSMA-12 showed slightly higher kidney retention (12.3 ± 8.0% ID/g) than [99mTc]Tc-N4-PSMA-13 and [99mTc]Tc-N4-PSMA-21 (6.6 ± 4.8% ID/g and 4.6 ± 1.4% ID/g, respectively) which was, however, not statistically significant (P > 0.81). In clear contrast to the N4-PSMA radioligands, very high activity retention in the kidney was found for [99mTc]Tc-PSMA-I&S (191 ± 26% ID/g, > 15-fold higher than that of [99mTc]Tc-N4-PSMA-12). Significantly higher activity retention after injection of [99mTc]Tc-PSMA-I&S at 6 h p.i. was also present in several other organs such as lungs, spleen, adrenals and parotid gland (P < 0.001 each). The higher activity uptake of [99mTc]Tc-PSMA-I&S in tumors, however, was less pronounced (15.6 ± 2.8% ID/g). The corresponding differences to the novel N4-PSMA radioligands were not statistically significant (P > 0.27). Efficient activity clearance from the blood pool was observed for all radioligands. The lowest blood activity level at 6 h p.i. was found for [99mTc]Tc-N4-PSMA-12 (0.0200 ± 0.0044% ID/g), which correlates with its low logD7.4 and low PPB. Blood activity levels of [99mTc]Tc-N4-PSMA-13, [99mTc]Tc-N4-PSMA-21 and [99mTc]Tc-PSMA-I&S were increased by 1.6-, 5.4- and 3.6-fold, respectively, as compared to [99mTc]Tc-N4-PSMA-12.
Tumor-to-background ratios (TBR)
As depicted in Fig. 5, [99mTc]Tc-N4-PSMA-12 showed the highest TBR among all radioligands throughout the majority of organs. It is noteworthy, that in direct comparison with [99mTc]Tc-PSMA-I&S, [99mTc]Tc-N4-PSMA-12 showed increased TBR for every analyzed organ and blood, thus demonstrating its notably superior clearance properties. In particular, a threefold T/blood-ratio (658 ± 147 vs 219 ± 62) and an even 20-fold T/kidney-ratio (1.64 ± 1.29 vs 0.08 ± 0.01) represent important advances towards optimized pharmacokinetics. Although less pronounced, improvements were also found for the TBR of [99mTc]Tc-N4-PSMA-13 and [99mTc]Tc-N4-PSMA-21. A tabular overview of TBR is provided in Additional file 1: Table S4.
With the N4-PSMA ligand design we aimed to create a versatile structural platform that ensures high PSMA affinity and reliable complexation of technetium-99m while also allowing for flexible modifications to adjust the pharmacokinetic profile of the entire ligand. To reach this goal we followed our expertise acquired in the development of theranostic rhPSMA ligands, where the combination of an EuE binding motif and a SiFA-moiety addressing the remote arene binding site has led to a series of highly potent PSMA tracers for imaging and therapy [23, 24]. To retain high affinity, while ensuring low lipophilicity of the new tracers, a less lipophilic SiOH-moiety (formally a hydrolyzed SiFA) was preferred. For complexation of technetium-99m a tetraamine (N4) chelator was chosen, as this chelating system exhibits excellent in vivo stability and confers high hydrophilicity to peptidic radioligands [29, 30]. A further advantage over N3S-based chelating systems such as mercaptoacetyltriserine is the absence of chemically reactive thiol-groups which might limit the shelf-live of radioligand precursors, an oftentimes neglected aspect in early radioligand development. Finally, the incorporation of a variable amino acid afforded three novel ligands with distinct properties in vitro and in vivo.
Slow whole-body clearance and in part hepatobiliary excretion of [99mTc]Tc-PSMA-I&S is assumed to be caused by high PPB and increased lipophilicity compared to other PSMA-addressing radiometal chelates . Therefore, a main focus in the design of the novel ligands was set on reduced lipophilicity and PPB. Fortunately, these objectives were met by all three N4-PSMA compounds. As expected, the intrinsic lipophilicity of the variable amino acid (logP: Phe > (4-NH2)-Phe > Glu)  translated into similar trends for lipophilicity and PPB of the corresponding radioligands (logD7.4 and PPB: [99mTc]Tc-PSMA-I&S > [99mTc]Tc-N4-PSMA-13 > [99mTc]Tc-N4-PSMA-21 > [99mTc]Tc-N4-PSMA-12). Especially [99mTc]Tc-N4-PSMA-12 combines a favorable lipophilicity, comparable to diagnostic rhPSMA compounds , and a PPB that is significantly lower than for [99mTc]Tc-PSMA-I&S, [68Ga]Ga/[177Lu]Lu-PSMA-I&F  or [99mTc]Tc-EuK-(SO3)Cy5-mas3  (all ligands developed for PSMA-guided surgery) and comparable to fast-clearing [177Lu]Lu-PSMA-617 . In agreement with many prior studies [25,26,27], these findings underline how the pharmacokinetically relevant properties of a radioligand can be shaped in a rational fashion by thoughtful structural modifications.
Even though [99mTc]Tc-PSMA-I&S showed favorable dosimetry in patients  and application in RGS suggests superiority over conventional salvage surgery , we have to admit that [99mTc]Tc-PSMA-I&S is not yet the optimal radioligand for RGS. This is exemplified by a study among 31 patients by Maurer et al. who reported successful resection of all lesions detected on prior PSMA-PET and even additional lesions as small as 3 mm . However, the same study revealed that in 12 of 86 resected tissue specimens that were classified PSMA-negative according to γ-probe measurements, histochemical analysis discovered previously unidentified metastatic lesions.
The obvious need for higher sensitivity in RGS is, from a radiopharmaceutical perspective, a need for an optimized radioactive probe providing higher TBR during surgery. Thus, to assess TBR of our novel 99mTc-labeled N4-PSMA ligands, biodistribution studies at 6 h p.i. were performed. This rather long distribution time comes with the limitation of scarce comparability with literature, where mostly time-points of 1 h or 4 h were investigated. However, RGS is performed around 20–24 h p.i. in patients [13, 19, 36] and, based on the rule of thumb of approximately fourfold faster metabolism in mice compared to men, we chose a distribution time of 6 h to simulate TBR at the time of surgery as accurately as possible. In that context, our preclinical findings on the in vivo performance of [99mTc]Tc-N4-PSMA ligands represent a remarkable development. While similar high uptake in LNCaP-xenografts was observed at 6 h p.i., the clearance of the novel ligands from most background tissue was significantly improved compared to [99mTc]Tc-PSMA-I&S. In addition, drastically and favorably reduced kidney retention compared to [99mTc]Tc-PSMA-I&S was found to be a common feature of the new ligands, which can probably be attributed to their shared molecular scaffold derived from rhPSMA-compounds [23, 24], while being pronounced by the use of the hydrolyzed SiFA moiety. This finding is of particular interest, as high renal activity accumulation may interfere with accurate lesion detection during RGS . Nevertheless, clinical studies are necessary to validate whether our preclinical findings also apply to the human situation. To an even greater extend, incomplete clearance of [99mTc]Tc-PSMA-I&S from the blood pool and thus a suboptimal T/blood-ratio can affect the accuracy of RGS . In this regard, the 3.6-fold decreased blood activity at 6 h p.i. represents another distinct advantage of [99mTc]Tc-N4-PSMA-12 and emphasizes the positive influence of the negatively charged amino acid d-Glu towards accelerated clearance kinetics. Compared to [99mTc]Tc-N4-PSMA-12, slightly higher uptake in blood and several background organs such as heart, lung, liver, parotid gland and submandibular gland were observed for [99mTc]Tc-N4-PSMA-13 and [99mTc]Tc-N4-PSMA-21, which can be attributed to the incorporation of the aromatic amino acids d-Phe and d-(4-NH2)Phe conferring higher lipophilicity and plasma protein binding to these compounds. A further possible limitation of [99mTc]Tc-PSMA-I&S is background activity in the bowel hampering the detection of lesions with low signal strength during surgery. In this regard, when completely ignoring the significantly improved T/kidney ratio of [99mTc]Tc-N4-PSMA-12 and when taking into account only the hepatic and intestinal uptake of [99mTc]Tc-PSMA-I&S and [99mTc]Tc-N4-PSMA-12 (no statistically significant difference observed, P > 0.19 and P > 0.36, respectively), we would expect at least similar performance of [99mTc]Tc-PSMA-I&S and [99mTc]Tc-N4-PSMA-12 in men. Beyond that, the finding that TBR of blood and all analyzed organs (see Fig. 5) obtained with [99mTc]Tc-N4-PSMA-12 are higher than that of [99mTc]Tc-PSMA-I&S clearly demonstrates the superior pharmacokinetic profile of that radioligand. Finally, as the only apparent advantage of [99mTc]Tc-N4-PSMA-13 and [99mTc]Tc-N4-PSMA-21 over [99mTc]Tc-N4-PSMA-12, namely a slightly decreased kidney retention, was not statistically significant (P > 0.81), and based on the aforementioned superior overall pharmacokinetic profile of [99mTc]Tc-N4-PSMA-12, the latter was identified as most promising compound.
Besides [99mTc]Tc-PSMA-I&S, the feasibility of PSMA-targeted RGS using [99mTc]Tc-MIP-1404, a tracer originally developed for SPECT-imaging, was recently described in a small cohort of nine patients . In a preclinical evaluation by Hillier et al. this tracer had shown a tissue distribution profile at 4 h p.i. which is highly similar to our data for [99mTc]Tc-N4-PSMA-12 (see Additional file 1: Fig. S2) . Surprisingly and in contrast to the pharmacokinetics observed in mice, biodistribution studies in patients revealed high hepatic uptake and delayed clearance for [99mTc]Tc-MIP-1404  indicating limited transferability of preclinical data to the human situation for this radioligand. Consistent with the similar patient dosimetry reported for [99mTc]Tc-PSMA-I&S and [99mTc]Tc-MIP-1404 [21, 35], the latter yielded comparable results in the recent RGS study . This example underlines not only the need for an optimized radioactive probe in PSMA-targeted RGS but also that, ultimately, clinical studies will be needed to assess whether the promising performance of [99mTc]Tc-N4-PSMA-12 in mice will also translate into improved outcomes of RGS in patients.
To facilitate future clinical translation, we developed a protocol for GMP-production of [99mTc]Tc-N4-PSMA-12 (see Fig. 6). As the simple, reliable, one-step process complies with basic nuclear medicine infrastructure and established clinical workflows and procedures, it provides an important basis for widespread availability of [99mTc]Tc-N4-PSMA-12 and may contribute to minimize the logistic hurdle for a first clinical application.
In summary, the rational design, development and comparative preclinical evaluation of three novel 99mTc-labeled PSMA inhibitors resulted in the identification of [99mTc]Tc-N4-PSMA-12 as lead candidate. Compared to [99mTc]Tc-PSMA-I&S, this novel radioligand showed a significantly improved pharmacokinetic profile, 3.6-fold reduced blood activity, 15-fold decreased kidney activity and improved TBR for blood and all organs. Furthermore, a clinically suited radiolabeling process is suggested rendering [99mTc]Tc-N4-PSMA-12 a highly attractive candidate for clinical application in RGS.
Based on the promising data presented in this preclinical work, a first clinical study with [99mTc]Tc-N4-PSMA-12 is highly warranted. It can be expected that this tracer has the potential to overcome current limitations obtained with [99mTc]Tc-PSMA-I&S and thus might pave the way towards a broader future use of PSMA-targeted RGS in the therapy of patients with biochemical recurrent PCa.
Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
High performance liquid chromatography
Lymph node metastases
Metastatic castration resistant prostate cancer
Phosphate buffered saline
Positron emission tomography
Plasma protein binding
Prostate-specific membrane antigen
Silicon fluoride acceptor
Sentinel lymph node dissection
Single photon emission computed tomography
Thin layer chromatography
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur Urol. 2020;77:508–47. https://doi.org/10.1016/j.eururo.2020.01.012.
Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, et al. Prostate-specific membrane antigen PET in prostate cancer. Radiology. 2021;299:248–60. https://doi.org/10.1148/radiol.2021202771.
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97. https://doi.org/10.1007/s00259-013-2660-z.
Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, et al. PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol. 2016;18:411–9. https://doi.org/10.1007/s11307-016-0957-6.
Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, et al. 99mTc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. Prostate. 2018;78:54–63. https://doi.org/10.1002/pros.23444.
Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169–76. https://doi.org/10.2967/jnumed.115.158550.
Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20. https://doi.org/10.2967/jnumed.114.147413.
Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148–58. https://doi.org/10.1007/s00259-018-4096-y.
Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:893–903. https://doi.org/10.1007/s00259-020-05022-3.
Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for therapy of prostate cancer. Semin Nucl Med. 2020;50:133–40. https://doi.org/10.1053/j.semnuclmed.2020.02.004.
Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721–8. https://doi.org/10.1007/s00259-019-04612-0.
Maurer T, Graefen M, van der Poel H, Hamdy F, Briganti A, Eiber M, et al. Prostate-specific membrane antigen-guided surgery. J Nucl Med. 2020;61:6–12. https://doi.org/10.2967/jnumed.119.232330.
Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. 99mTechnetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;75:659–66. https://doi.org/10.1016/j.eururo.2018.03.013.
Schottelius M, Wirtz M, Eiber M, Maurer T, Wester HJ. [111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015;5:68. https://doi.org/10.1186/s13550-015-0147-6.
Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58:235–42. https://doi.org/10.2967/jnumed.116.178939.
Horn T, Kronke M, Rauscher I, Haller B, Robu S, Wester HJ, et al. Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;76:517–23. https://doi.org/10.1016/j.eururo.2019.03.045.
Knipper S, Tilki D, Mansholt J, Berliner C, Bernreuther C, Steuber T, et al. Metastases-yield and prostate-specific antigen kinetics following salvage lymph node dissection for prostate cancer: a comparison between conventional surgical approach and prostate-specific membrane antigen-radioguided surgery. Eur Urol Focus. 2019;5:50–3. https://doi.org/10.1016/j.euf.2018.09.014.
Rauscher I, Horn T, Eiber M, Gschwend JE, Maurer T. Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands. World J Urol. 2018;36:603–8. https://doi.org/10.1007/s00345-018-2200-3.
de Barros HA, van Oosterom MN, Donswijk ML, Hendrikx J, Vis AN, Maurer T, et al. Robot-assisted prostate-specific membrane antigen-radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective feasibility study. Eur Urol. 2022;82:97–105. https://doi.org/10.1016/j.eururo.2022.03.002.
Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large multi-institutional analysis. Eur Urol. 2019;75:176–83. https://doi.org/10.1016/j.eururo.2018.09.009.
Urban S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, et al. Radiation dosimetry of 99mTc-PSMA I&S: a single-center prospective study. J Nucl Med. 2021;62:1075–81. https://doi.org/10.2967/jnumed.120.253476.
Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020;10:45. https://doi.org/10.1186/s13550-020-00635-z.
Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, et al. Radiohybrid ligands: a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors. J Nucl Med. 2020;61:735–42. https://doi.org/10.2967/jnumed.119.234922.
Wurzer A, Kunert JP, Fischer S, Felber V, Beck R, De Rose F, et al. Synthesis and preclinical evaluation of 177Lu-labeled radiohybrid PSMA ligands (rhPSMAs) for endoradiotherapy of prostate cancer. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263371.
Hensbergen AW, Buckle T, van Willigen DM, Schottelius M, Welling MM, van der Wijk FA, et al. Hybrid tracers based on cyanine backbones targeting prostate-specific membrane antigen: tuning pharmacokinetic properties and exploring dye-protein interaction. J Nucl Med. 2020;61:234–41. https://doi.org/10.2967/jnumed.119.233064.
Eder AC, Schafer M, Schmidt J, Bauder-Wust U, Roscher M, Leotta K, et al. Rational linker design to accelerate excretion and reduce background uptake of peptidomimetic PSMA-targeting hybrid molecules. J Nucl Med. 2021;62:1461–7. https://doi.org/10.2967/jnumed.120.248443.
Wurzer A, Parzinger M, Konrad M, Beck R, Gunther T, Felber V, et al. Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics. EJNMMI Res. 2020;10:149. https://doi.org/10.1186/s13550-020-00740-z.
Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4:63. https://doi.org/10.1186/s13550-014-0063-1.
Abiraj K, Ursillo S, Tamma ML, Rylova SN, Waser B, Constable EC, et al. The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist. EJNMMI Res. 2018;8:75. https://doi.org/10.1186/s13550-018-0428-y.
Fani M, Weingaertner V, Kolenc Peitl P, Mansi R, Gaonkar RH, Garnuszek P, et al. Selection of the first 99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation-preclinical assessment of two optimized candidates. Pharmaceuticals. 2020;14:19. https://doi.org/10.3390/ph14010019 (Basel).
Kubyshkin V. Experimental lipophilicity scale for coded and noncoded amino acid residues. Org Biomol Chem. 2021;19:7031–40. https://doi.org/10.1039/d1ob01213d.
Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, et al. Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. J Nucl Med. 2019;60:71–8. https://doi.org/10.2967/jnumed.118.212720.
Benesova M, Umbricht CA, Schibli R, Muller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934–46. https://doi.org/10.1021/acs.molpharmaceut.7b00877.
Koehler D, Sauer M, Klutmann S, Apostolova I, Lehnert W, Budaus L, et al. Feasibility of 99mTc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.122.263892.
Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med. 2014;55:1791–8. https://doi.org/10.2967/jnumed.114.140426.
Mix M, Schultze-Seemann W, von Buren M, Sigle A, Omrane MA, Grabbert MT, et al. 99mTc-labelled PSMA ligand for radio-guided surgery in nodal metastatic prostate cancer: proof of principle. EJNMMI Res. 2021;11:22. https://doi.org/10.1186/s13550-021-00762-1.
Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013;54:1369–76. https://doi.org/10.2967/jnumed.112.116624.
Open Access funding enabled and organized by Projekt DEAL. HJW receives funding from the SFB 824 (Deutsche Forschungsgemeinschaft, Bonn, Germany, Sonderforschungsbereich 824, Project B11 and Z01).
Ethics approval and consent to participate
All animal experiments were conducted in accordance with general animal welfare regulations in Germany (German animal protection act, in the edition of the announcement, dated May 18th, 2006, as amended by Article 280 of June 19th 2020, approval no. ROB-55.2-1-2532.Vet_02-18-109 by the General Administration of Upper Bavaria) and the institutional guidelines for the care and use of animals. The study was carried out in compliance with the ARRIVE guidelines. This article does not contain any studies with human participants.
Consent for publication
JPK and HJW are listed as inventors in patent applications for some silicon-containing PSMA compounds. HJW receives funding from the SFB 824 (Deutsche Forschungsgemeinschaft, Bonn, Germany, Sonderforschungsbereich 824, Project B11 and Z01). HJW is founder and shareholder of Scintomics GmbH, Fuerstenfeldbruck, Germany. No other potential conflicts of interest relevant to this article exist.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kunert, JP., Müller, M., Günther, T. et al. Synthesis and preclinical evaluation of novel 99mTc-labeled PSMA ligands for radioguided surgery of prostate cancer. EJNMMI Res 13, 2 (2023). https://doi.org/10.1186/s13550-022-00942-7
- Radioguided surgery
- Prostate cancer